FOTIVDA tivozanib

Drug Class

VEGFR tyrosine kinase inhibitor

Mechanism

Selectively inhibits VEGFR-1, -2, and -3 receptor tyrosine kinases, blocking tumor vascularization and cell growth.

Approved Indication

Relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies, per its FDA approval.

What This Means For Patients

Fotivda is a targeted oral medication for adult patients with advanced renal cell carcinoma (kidney cancer) that has recurred or progressed despite prior treatments. It inhibits the pathways responsible for tumor blood vessel growth, and is available in Lecheng.

Regulatory Approvals

• FDA — approved (2021) — label

Pivotal Clinical Evidence

• TIVO-3 — Rini et al., Lancet Oncol 2020 (NCT02627963) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212904s000lbl.pdf